The gene therapy developed by the South Korean pharmaceutical company has been classified as an orphan drug by the USFDA during phase 1 clinical trials due to the effectiveness it displayed with ALS patients. The phase 2 trial is expected to last 9 months with 84 patients participating in the process.
The only USFDA-approved drug for the progressive neuromuscular disease hitherto is Rilutek, marketed by Sanofi, a French pharmaceutical firm.
A spokesperson for Viromed added that VM202 is expected to extend life expectancy and improve body control for ALS patients.
VM202 has also been eyed as a cure for diabetic neuropathy as it entered phase 3 clinical trials in the US in September, to be assessed further for the purpose.
By Jung Min-kyung (firstname.lastname@example.org)